Apogee Therapeutics, Inc. Common Stock

Apogee's 20% short float stands out as notably elevated, signaling meaningful skepticism despite the company's $6.3B valuation and neutral 51.8 RSI. The absence of a P/E ratio indicates unprofitability, which combined with heavy short interest suggests the market questions whether the clinical-stage biotech can deliver on its pipeline promise. The stock sits below its 52-week high, and that substantial short position creates potential squeeze dynamics if clinical data proves compelling. The setup reflects classic biotech risk-reward: significant conviction on both bull and bear sides, with catalysts likely to drive volatile repricing.